Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.
about
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast functionEctopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cellsGalectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myelomaCombination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.Apoptosis of multiple myeloma.A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma.Annatto constituent cis-bixin has selective antimyeloma effects mediated by oxidative stress and associated with inhibition of thioredoxin and thioredoxin reductaseMolecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell linesIn vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cellsPreclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cellsChaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress.Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironmentSyrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death.The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone DiseaseTargeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.Surface-tension driven open microfluidic platform for hanging droplet culture.Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple MyelomaDexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors.Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell linesDecursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells.Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cellsIncreased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation.Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d.Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.Environmental-mediated drug resistance: a target for multiple myeloma therapy.Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.Expression of peroxiredoxins I and IV in multiple myeloma: association with immunoglobulin accumulation.Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.
P2860
Q24297354-5EDD6FF0-8866-4CE2-87AA-6B9DAF2E017CQ28542491-EA672674-E116-4547-B259-5F69045FCC32Q28742668-3E7F50EA-D2A3-4B15-B098-E8F9629BB8D9Q33627051-07E36E1E-CFE9-4651-AD2D-1B1174897DC9Q33902726-ABB64419-0379-49B1-AA2D-CAD7BB82206DQ33930178-5D1A3131-E07B-404D-9F82-C9BC842D9C12Q33976734-3D4CFE1B-E86E-499B-9D63-5F4A9AAAF042Q34134986-7B06BBDB-83E4-4B32-9353-C5EF733156CBQ34200686-2246157C-1B36-4CFF-9EA1-97FB18103828Q34222602-F7C654E3-189B-4B26-A18C-7B64CACDDC32Q34608271-BAB3CBD9-85DB-40F6-9FBB-856C846893D8Q35128148-BC035D42-D570-43A5-BC9B-9B96A56836C4Q35167162-CAC4962E-1452-4400-AFAB-0A70C1B898DBQ35337908-1965757A-7D80-464C-BF81-6589E0E7FA0CQ35750893-3F627AE1-307B-4862-B401-398DE92E809EQ35802226-08E2407C-67FF-4B2D-A3ED-65813ED924A9Q35933211-1F0A683C-1A10-43BD-B20A-6C59AE74711CQ36011988-7748888D-2F5B-4A9F-8978-D74D4ACCB043Q36172671-2D70C7EF-D091-48D8-B586-D3A5BE4CC59CQ36295294-C5DB6EEA-643A-46D2-B5B0-72E59E187BF2Q36462782-1C985E96-B30B-487E-8104-7038CA8A27A8Q36470302-93C996D9-D428-48BF-91C5-E1D0DD4CD423Q36589122-7D6C383B-677E-4E71-8A65-B354D8FEC592Q36642956-6232FA90-0F7E-4543-A668-3C5D549089A1Q36835067-6E3C82E5-4F91-466F-9F67-50C9BA8A5931Q36880024-0D3B0A83-6C59-4A1A-B9D3-DA762873A0BFQ36933281-A8CE604A-F4FA-400E-88BC-7C6427A6D447Q37161467-1E0677D0-9BCF-4341-B551-5C6F65F0DFD9Q37201872-D67C8D01-B91F-4783-AADF-170FE254166BQ37424554-0BFA05F2-B606-4DA0-BF99-2E9768A7C3BDQ37636618-48FCB3CD-99C4-44E6-9240-035455C04A1EQ37694678-AA1F9607-E096-4EAA-B141-B02EAF212433Q37810085-B65F3C3B-DB14-444C-8B45-2E8AE38E2E1AQ38676278-8E318E49-A78B-413A-81EA-FA9D1DC223ABQ38743088-B94E5E73-ACA2-46CB-A8E0-EA9AC68E0799Q38743857-A9884985-3F15-4BFD-8F36-BE276A7B6BDEQ39143899-A930C0FA-319D-4367-BED1-2EC1339D9D7CQ39174431-915F6932-7FEB-4AFC-8354-E013C17C149CQ39223255-89FC40FF-DD27-4592-8A52-E7250064B4E6Q39421121-BF3C3B8D-01B8-4CAC-BB1F-395B461C338B
P2860
Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Characterization of the MM.1 h ...... itive and -resistant MM cells.
@ast
Characterization of the MM.1 h ...... itive and -resistant MM cells.
@en
type
label
Characterization of the MM.1 h ...... itive and -resistant MM cells.
@ast
Characterization of the MM.1 h ...... itive and -resistant MM cells.
@en
prefLabel
Characterization of the MM.1 h ...... itive and -resistant MM cells.
@ast
Characterization of the MM.1 h ...... itive and -resistant MM cells.
@en
P2093
P4510
P1476
Characterization of the MM.1 h ...... itive and -resistant MM cells.
@en
P2093
Chunguang Ma
Dharminder Chauhan
Nancy L Krett
Stephanie Greenstein
Steven T Rosen
Teru Hideshima
Yoshihiro Kurosawa
P304
P356
10.1016/S0301-472X(03)00023-7
P577
2003-04-01T00:00:00Z